Skip to main content

Table 4 Status of tracer indicator scores for all cancer tracer indicators at each level of health facility (n = 323)

From: Assessing service availability and readiness to manage cervical cancer in Bangladesh

Tracer Items

Total

Tertiary & Specialized Hospital

District Hospital

MCWC

UHC

NGO/Private Hospital

Staff and guideline [n (index score in %)]

 Oncologists

31 (9.6)

7 (100.0)

9 (15.5)

0 (0.0)

1 (0.8)

14 (18.9)

 Palliative care specialist

4 (1.2)

3 (42.9)

1 (1.7)

0 (0.0)

0 (0.0)

0 (0.0)

 Trained Nurse

9 (2.8)

5 (71.4)

2 (3.4)

0 (0.0)

1 (0.8)

1 (1.4)

 Guideline a

41 (12.7)

7 (100.0)

10 (17.2)

3 (5.0)

11 (8.9)

10 (13.5)

 Training a

32 (9.9)

7 (100.0)

6 (10.3)

3 (5.0)

13 (10.5)

3 (4.1)

Equipment [n (index score in %)]

 Beds available for cancer patients

26 (8.0)

7 (100.0)

7 (12.1)

0 (0.0)

8 (6.5)

4 (5.4)

 Speculum a

152 (47.1)

7 (100.0)

36 (62.1)

28 (46.7)

57 (46.0)

24 (32.4)

Diagnostic facility [n (index score in %)]

 Acetic Acid a

136 (42.1)

6 (85.7)

36 (62.1)

27 (45.0)

53 (42.7)

14 (18.9)

 Sputum for Cytology

80 (24.8)

7 (100.0)

20 (34.5)

1 (1.7)

27 (21.8)

25 (33.8)

 Stool occult blood test (OBT)

75 (23.2)

7 (100.0)

14 (24.1)

1 (1.7)

21 (16.9)

32 (43.2)

 Cancer antigen 15.3 (CA 15.3)

24 (7.4)

5 (71.4)

3 (5.2)

1 (1.7)

1 (0.8)

14 (18.9)

 Cancer antigen 19.9 (CA 19.9)

23 (7.1)

5 (71.4)

3 (5.2)

1 (1.7)

1 (0.8)

13 (17.6)

 Carcinoembryonic antigen (CEA)

23 (7.1)

5 (71.4)

3 (5.2)

1 (1.7)

1 (0.8)

13 (17.6)

 Cancer antigen 125 (CA125)

23 (7.1)

5 (71.4)

3 (5.2)

1 (1.7)

1 (0.8)

13 (17.6)

 Alpha Keto Protein

25 (7.7)

5 (71.4)

3 (5.2)

1 (1.7)

2 (1.6)

14 (18.9)

 Endoscopy of upper gastrointestinal tract

43 (13.3)

7 (100.0)

10 (17.2)

0 (0.0)

4 (3.2)

22 (29.7)

 Colonoscopy

35 (10.8)

7 (100.0)

8 (13.8)

0 (0.0)

2 (1.6)

18 (24.3)

 Pituitary tumor-transforming gene 1-binding factor (PBF)

55 (17.0)

7 (100.0)

14 (24.1)

0 (0.0)

7 (5.6)

27 (36.5)

 Bone Marrow Study

21 (6.5)

7 (100.0)

2 (3.4)

0 (0.0)

1 (0.8)

11 (14.9)

 Biopsy for Histopathology

35 (10.8)

7 (100.0)

9 (15.5)

0 (0.0)

1 (0.8)

18 (24.3)

 Fine Needle Aspiration Cytology (FNAC)

35 (10.8)

6 (85.7)

8 (13.8)

0 (0.0)

1 (0.8)

20 (27.0)

Medicines [n (index score in %)]

 Hydrocortisone

150 (46.4)

7 (100.0)

33 (56.9)

18 (30.0)

57 (46.0)

35 (47.3)

 Pheniramine

61 (18.9)

5 (71.4)

11 (19.0)

10 (16.7)

17 (13.7)

18 (24.3)

 Ondanseron

84 (26.0)

6 (85.7)

20 (34.5)

6 (10.0)

22 (17.7)

30 (40.5)

 Haloperidol

40 (12.4)

6 (85.7)

11 (19.0)

3 (5.0)

4 (3.2)

16 (21.6)

 Morphin injection

28 (8.7)

6 (85.7)

8 (13.8)

2 (3.3)

4 (3.2)

8 (10.8)

 Morphin tablet

23 (7.1)

4 (57.1)

7 (12.1)

1 (1.7)

4 (3.2)

7 (9.5)

 Lorazepam

47 (14.6)

5 (71.4)

12 (20.7)

4 (6.7)

10 (8.1)

16 (21.6)

 Hyoscine butylebromide

65 (20.1)

7 (100.0)

13 (22.4)

6 (10.0)

21 (16.9)

18 (24.3)

 Broad Spectrum Antibiotics

151 (46.7)

7 (100.0)

37 (63.8)

20 (33.3)

55 (44.4)

32 (43.2)

 Chemotherapeutic drugs

17 (5.3)

5 (71.4)

2 (3.4)

1 (1.7)

3 (2.4)

6 (8.1)

  1. aindicators that are specific for determining service readiness for cervical cancer patients